Knowledge

In February 2026, major North American health networks fully integrated Cala kIQ neuromodulation devices into cloud-based clinic procurement systems. This enables just-in-time (JIT) inventory management, allowing clinics to order wearables automatically as needed, cutting storage costs and ensuring patient access to tremor therapy. HHG GROUP highlights this as a supply chain game-changer. Medical Equipment Store […]

AI‑driven procurement software for healthcare providers is transforming how hospitals and clinics source medical technology, including advanced devices like the Cala kIQ system. Using predictive analytics, new platforms launched in Q1 2026 forecast when patients with Essential Tremor are most likely to need device upgrades, aligning purchases with clinical demand. This shift turns the Cala

Tracking hospital equipment utilization for neuromodulation devices such as Cala kIQ units improves ROI by identifying real usage patterns, reducing idle time, and supporting data-driven purchasing decisions. Clinics achieving up to 95% daily utilization can justify fleet expansion, optimize patient access, and lower operational costs while maximizing revenue from each device across the care continuum.

Cala Health’s expansion of OEM services is transforming neurotechnology by enabling companies to license its TAPS architecture for customized device development. This approach reduces development time, lowers costs, and promotes standardization across medical hardware. As adoption grows, it could enhance innovation, improve patient access to advanced therapies, and strengthen compatibility across the global healthcare ecosystem.

Yes, on April 16, 2026, the U.S. Food and Drug Administration granted 510(k) clearance for the Cala kIQ Plus, an updated wrist‑worn neurostimulation system for on‑demand tremor relief in Essential Tremor and Parkinson’s Disease. The device builds on TAPS Therapy with adaptive calibration and new therapy modes, offering greater precision, comfort, and clinical utility than

The wearable tremor therapy market has surpassed $870 million in 2026, fueled by rising neurological disorders, demand for non-drug treatments, and advances in wearable neuromodulation technology. These devices provide targeted, non-invasive relief for tremors, improving patient outcomes while reducing reliance on pharmaceuticals and supporting a broader shift toward electronic medicine in modern healthcare systems. Medical

By mid-2026, the supply chain for specialized microchips in neuromodulation devices has fully stabilized. This enables faster fulfillment cycles, cutting lead times for clinics and ensuring on-demand therapy availability amid global healthcare demands. Medical Equipment Store | New & Used Devices | HHG Marketplace What Are Medical Microcontrollers in Neuromodulation Devices? Medical microcontrollers are specialized

The Cala kIQ Plus is an FDA-cleared, next-generation wearable TAPS system designed to provide personalized, non-invasive relief for hand tremors associated with Essential Tremor and Parkinson’s Disease. By utilizing adaptive calibration and intelligent software-driven therapy modes, it delivers precise neurostimulation to the median and radial nerves, offering patients a tailored and effective alternative to pharmacological

In 2026, the medical laser market has reached a critical divergence. PicoWay has emerged as the dominant force for multi-colored tattoo removal and diverse skin tones due to its 532/730/1064nm versatility. Conversely, PicoSure’s 755nm Alexandrite technology remains the industry’s gold standard specifically for targeting stubborn blue and green inks, catering to specialized aesthetic clinics and

With the global medical laser market projected to reach $4.76 billion in 2026, many clinics are turning to the resale market to combat high inflation and rising supply chain costs. A 15% increase in demand for refurbished aesthetic lasers proves that savvy practitioners are prioritizing high-quality, pre-owned units from brands like Cynosure and Candela to